Home » Stocks » Athersys

Athersys, Inc. (ATHX)

Stock Price: $2.31 USD 0.05 (2.21%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
After-hours: $2.30 -0.01 (-0.43%) Aug 12, 5:47 PM

Stock Price Chart

Key Info

Market Cap 456.00M
Revenue (ttm) 10,000
Net Income (ttm) -55.95M
Shares Out 197.40M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $2.31
Previous Close $2.26
Change ($) 0.05
Change (%) 2.21%
Day's Open 2.37
Day's Range 2.25 - 2.45
Day's Volume 3,952,279
52-Week Range 1.13 - 4.38

More Stats

Market Cap 456.00M
Enterprise Value 375.30M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 197.40M
Float 178.61M
EPS (basic) -0.34
EPS (diluted) -0.34
FCF / Share -0.23
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 23.60M
Short Ratio 8.04
Short % of Float 13.28%
Beta -1.71
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 45,600.32
PB Ratio 26.92
Revenue 10,000
Operating Income -56.42M
Net Income -55.95M
Free Cash Flow -43.94M
Net Cash 80.71M
Net Cash / Share 0.41
Gross Margin -334,120.00%
Operating Margin -564,230.00%
Profit Margin -559,540.00%
FCF Margin -439,440.00%
ROA -50.49%
ROE -114.86%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.25*
(257.14% upside)
Low
5.00
Current: $2.31
High
12.00
Target: 8.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue5.6324.293.7117.3511.951.622.448.7110.348.94
Revenue Growth-76.81%555.1%-78.62%45.19%636.17%-33.43%-72%-15.82%15.72%-
Gross Profit5.6324.293.7117.3511.951.622.448.7110.348.94
Operating Income-45.49-25.05-33.28-15.03-17.17-29.01-24.46-16.00-13.78-11.51
Net Income-44.58-24.28-32.24-15.34-16.42-22.08-30.74-14.74-13.75-11.38
Shares Outstanding15213711284.7282.1476.9557.6732.5623.2418.93
Earnings Per Share-0.29-0.18-0.29-0.18-0.20-0.31-0.53-0.45-0.59-0.60
Operating Cash Flow-35.33-13.35-24.02-10.93-13.76-25.79-22.78-17.67-14.49-10.59
Capital Expenditures-0.58-1.53-0.29-1.71-0.13-0.30-0.39-0.35-0.59-0.39
Free Cash Flow-35.91-14.88-24.30-12.64-13.90-26.09-23.17-18.01-15.08-10.98
Cash & Equivalents35.0451.0629.3214.7523.0326.1331.9525.5312.7815.18
Total Debt----0.190.180.180.17--
Net Cash / Debt35.0451.0629.3214.7522.8425.9431.7725.3612.7815.18
Assets41.6761.7333.5919.0625.1328.7234.1927.6015.7019.11
Liabilities18.4018.6110.227.885.417.8214.377.368.4010.10
Book Value23.2743.1223.3811.1819.7220.9019.8220.257.309.01
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Athersys, Inc.
Country United States
Employees 83
CEO Gil van Bokkelen

Stock Information

Ticker Symbol ATHX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ATHX

Description

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.